PK as A Therapeutic Target (P11286)

Target Name: Pyruvate Kinase

NCBI ID: P11286

Other Name(s): None

PK as A Therapeutic Target

Pyruvate Kinase (PK) is an enzyme that plays a critical role in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle. It is a key enzyme in the production of energy from glucose and fatty acids, and is also involved in the biosynthesis of amino acids and nucleotides. PK is a protein that consists of 456 amino acids and has a calculated pI of 2.9. PK is widely expressed in various cell types and is involved in many cellular processes, including metabolism, cell growth, and cell death.

Due to its involvement in a wide range of cellular processes, PK has been identified as a potential drug target. Studies have shown that inhibiting PK has potential therapeutic benefits for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In addition, PK has also been shown to be a potential biomarker for some diseases, such as cancer.

One of the main advantages of targeting PK is its potential to disrupt the citric acid cycle, which is a central metabolic pathway for many organisms. The citric acid cycle is involved in the production of energy from glucose and fatty acids, and is also involved in the biosynthesis of amino acids and nucleotides. By disrupting this pathway, PK can inhibit the production of energy and the biosynthesis of important molecules. This can have a wide range of therapeutic benefits, including the treatment of metabolic disorders, such as diabetes, and the treatment of cancer.

Another potential mechanism by which PK can be targeted is its role in cell signaling. PK is involved in the production of reactive oxygen species (ROS), which can act as a signaling molecule in response to various cellular stressors, including UV radiation, chemo- stress, and radiation. By inhibiting the production of ROS, PK can have a negative impact on cellular signaling and may be a potential target for therapeutic interventions aimed at reducing cellular stress.

In addition to its potential therapeutic benefits, PK is also a potential biomarker for a variety of diseases. For example, PK has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This suggests that targeting PK may be a promising approach for the development of new cancer therapies. Additionally, PK has also been shown to be overexpressed in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. This suggests that targeting PK may also be a promising approach for the development of new therapies for neurodegenerative diseases.

In conclusion, Pyruvate Kinase (PK) is an enzyme that plays a critical role in the citric acid cycle and has a wide range of cellular processes. PK has been identified as a potential drug target due to its involvement in the production of energy and the biosynthesis of important molecules, as well as its potential to disrupt cell signaling and act as a biomarker for various diseases. Further research is needed to fully understand the therapeutic potential of PK and to develop new treatments based on this target.

Protein Name: Pyruvate Kinase (nonspecified Subtype)

More Common Targets